News
An investigation has uncovered evidence of significant misreporting, raising new concerns about the approval and long-term ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive ...
Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...
18d
News-Medical.Net on MSNBMJ investigation raises new concerns over ticagrelor approval trialsIn a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval. For more than a decade, ...
The twice-daily pill is given to people with acute coronary syndrome -a sudden reduction of blood to the heart-reducing the ...
We all need to know how and why that happened." More information: Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca's billion dollar drug, The BMJ (2025). DOI: 10.1136/bmj.r1201 ...
As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.
Ticagrelor is a novel generation P2Y 12 receptor inhibitor, a first in class cyclopentyltriazolopyrimidine, with more potent antiplatelet effects than clopidogrel, but faster speed of offset, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results